Chronic inflammatory demyelinating polyneuropathy (CIDP): therapeutic updates, best practices, and emerging therapies (CME)

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic, acquired, autoimmune disorder affecting the peripheral nervous system. Occurring at an incidence of 4-9 people per 100,000, CIDP most commonly occurs in adults aged of 40 to 60, although it may also occur in children and the elderly. The pathophysiology of CIDP is not completely understood but involves several humoral and cell-mediated mechanisms. Symptoms of CIDP include progressive limb weakness, usually with a predilection for proximal muscles, and sensory loss and are monophasic and progress for 8 weeks or more.

Objective:

1. Describe the pathophysiology of CIDP such that it might inform treatment mechanisms
2. Identify the currently available and emerging pharmacotherapeutic treatments for management of CIDP and apply them to patient cases using evidence-based medicine
3. Modify an existing treatment plan for a specific patient with CIDP to optimize safety and efficacy following non-response to therapy
4. Describe non-pharmacological options to manage CIDP

Credit Designation:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians. ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.